Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

计划入组 7 人 · 首次发布于 2022 年 7 月 11 日

Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

计划入组 50 人 · 首次发布于 2026 年 5 月 6 日

Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

计划入组 264 人 · 首次发布于 2021 年 8 月 2 日

MuSK-CAART

Moschus berezovskii musk sac resin

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment

Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis